Fortis Life Sciences Partners with AccuGenomics to Expand Genomics Portfolio
March 29th, 2022
WALTHAM, MA- Fortis Life Sciences, a strategic platform company providing capital, expertise, and operational resources to grow founder-led life science companies, today announced it is the exclusive channel partner for AccuGenomics in the United States, with co-exclusive rights in Europe. Under the agreement, Fortis will help expand customer access to AccuGenomics’ patented SNAQ™-SEQ Internal Standards technology, the only commercial internal standards for next-generation sequencing (NGS).
SNAQ™-SEQ multiplex QC standards are essential for highly sensitive NGS applications. These standards eliminate the need for more costly external controls that take up valuable space in assay design. They are more accurate as each sample has an internal control rather than relying on representative controls being used for the entire assay.
Ken Yoon, Fortis' Chief Operating Officer, commented on the partnership, "We are delighted to be partnering with an innovative company like AccuGenomics. Their patented SNAQ technology will dramatically improve the ability of customers to trust the accuracy and sensitivity of their results, especially in the most demanding precision medical applications. We believe the technology and expertise of AccuGenomics, our commercial and operational capabilities will form a highly complementary, strategic partnership."
"Fortis Life Sciences is well aligned across the diagnostic, therapeutic, and pharmaceutical discovery sectors as a strategic distribution partner for AccuGenomics in the US and Europe. They will provide expertise and operational resources to help enable the growth and success of our company. Our focus is on improving the accuracy and sensitivity of challenging liquid biopsy applications like minimal residual disease (MRD) detection. This agreement with Fortis will accelerate the adoption of our differentiated internal spike in standards for targeted NGS assays like MRD while providing researchers and clinicians better access to our SNAQ technology, leading to more accurate and actionable variant calls across multiple precision medicine applications," said Dan Dilks, Senior Vice President, Business Development at AccuGenomics.
AccuGenomics is driven to improve the accuracy and performance of clinical sequencing for better patient outcomes. The rapid pace of innovation in NGS diagnostics continues to push the limits of detection for low abundance biomarkers, increasing the need to demonstrate the analytical performance of these tests for patients and healthcare providers. AccuGenomics is actively developing technology solutions that enable test developers and implementers to demonstrate the highest performance levels of their assay. SNAQTM-SEQ enables a host of highly sensitive NGS applications that improve ctDNA detection in liquid biopsy, SARS-CoV-2 pathogen screening, and rapid adventitious agent detection in cell therapy manufacturing. https://www.accugenomics.com
Fortis partners with diagnostics and life sciences companies to custom-design, validate, and manufacture proprietary solutions to solve their most difficult development problems. Fortis’ tailored approach and end-to-end capabilities accelerate the work of its customers as they bring the next generation of medicines and diagnostics to market. Fortis serves a global customer base and has offices across the world including four R&D sites and three GMP and ISO 13485 compliant manufacturing facilities in North America. To learn more about Fortis, please visit www.fortislife.com.
